These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 18676837

  • 1. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA.
    Cancer Res; 2008 Aug 01; 68(15):6145-53. PubMed ID: 18676837
    [Abstract] [Full Text] [Related]

  • 2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S, Lee SH, Dean NM, McMahon M.
    Cancer Res; 2005 Jun 01; 65(11):4870-80. PubMed ID: 15930308
    [Abstract] [Full Text] [Related]

  • 4. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb 01; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

  • 5. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD.
    J Clin Endocrinol Metab; 2007 Dec 01; 92(12):4712-8. PubMed ID: 17878251
    [Abstract] [Full Text] [Related]

  • 6. Spry2 expression correlates with BRAF mutation in thyroid cancer.
    Xu L, Zhou JL, Cohen M, Bar-Sagi D, Patel KN.
    Surgery; 2010 Dec 01; 148(6):1282-7; discussion 1287. PubMed ID: 21134562
    [Abstract] [Full Text] [Related]

  • 7. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA.
    Cancer Res; 2010 Nov 01; 70(21):8736-47. PubMed ID: 20959481
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.
    Clin Cancer Res; 2012 May 01; 18(9):2515-25. PubMed ID: 22392911
    [Abstract] [Full Text] [Related]

  • 9. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 10. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
    Wang J, Zhao Y, Kauss MA, Spindel S, Lian H.
    Eur J Cell Biol; 2009 Feb 15; 88(2):103-15. PubMed ID: 19058874
    [Abstract] [Full Text] [Related]

  • 11. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

  • 12. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 15; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 13. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK.
    J Endocrinol; 2011 Oct 15; 211(1):79-85. PubMed ID: 21795305
    [Abstract] [Full Text] [Related]

  • 14. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 15; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 15. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K.
    Med Sci Monit; 2018 May 08; 24():3002-3010. PubMed ID: 29737325
    [Abstract] [Full Text] [Related]

  • 16. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
    Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS.
    Clin Cancer Res; 2008 Jan 01; 14(1):230-9. PubMed ID: 18172275
    [Abstract] [Full Text] [Related]

  • 17. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan 01; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 18. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 01; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 19. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.
    J Hepatol; 2010 Jan 01; 52(1):79-87. PubMed ID: 19910069
    [Abstract] [Full Text] [Related]

  • 20. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E.
    Clin Cancer Res; 2007 Mar 01; 13(5):1576-83. PubMed ID: 17332304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.